What is Marinus Pharmaceuticals Financial Strength?
Marinus Pharmaceuticals has the Financial Strength Rank of 2. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.
Warning Sign:
Marinus Pharmaceuticals Inc displays poor financial strength. Usually, this is caused by too much debt for the company.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Marinus Pharmaceuticals did not have earnings to cover the interest expense.
Marinus Pharmaceuticals's debt to revenue ratio for the quarter that ended in Mar. 2024 was 2.45.
As of today, Marinus Pharmaceuticals's Altman Z-Score is -8.07.
Competitive Comparison of Marinus Pharmaceuticals's Financial Strength
For the Biotechnology subindustry, Marinus Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marinus Pharmaceuticals's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marinus Pharmaceuticals's Financial Strength distribution charts can be found below:
* The bar in red indicates where Marinus Pharmaceuticals's Financial Strength falls into.
Marinus Pharmaceuticals Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Marinus Pharmaceuticals's Interest Expense for the
months ended in Mar. 2024 was $-4.35 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-35.82 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $58.65 Mil.
Marinus Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is
| Marinus Pharmaceuticals did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Marinus Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Marinus Pharmaceuticals has a Z-score of -8.07, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -8.07 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marinus Pharmaceuticals (Marinus Pharmaceuticals) Business Description
Traded in Other Exchanges
Address
100 Matsonford Road, Suite 500, 5 Radnor Corporate Center, Radnor, PA, USA, 19087
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
Executives
| Christina Shafer |
officer: Chief Commercial Officer |
5 RADNOR CORPORATE CENTER, SUITE 500, 100 MATSONFORD ROAD, RADNOR PA 19087 |
| Scott Braunstein |
director |
C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
| Steven Pfanstiel |
officer: CFO |
5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087 |
| Joseph Hulihan |
officer: Chief Medical Officer |
5 RADNOR CORP CENTER SUITE 500, 100 MATSONFORD RD, RADNOR PA 19087 |
| Martha E Manning |
officer: VP, Gen. Counsel & Corp. Sec. |
700 PENNSYLVANIA DR, EXTON PA 19341 |
| Sarah B. Noonberg |
director |
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
| Marvin Johnson |
director |
C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, STE. 110, CHESTERBROOK PA 19087 |
| Elan Ezickson |
director |
AVEO PHARMACEUTICALS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139 |
| Charles Austin |
director |
5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087 |
| Fischer Seth H.z. |
director |
C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
| Christine Berni Silverstein |
director |
C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019 |
| Santiago Arroyo |
director |
C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142 |
| Sara Nochur |
director |
295 WOODCLIFF RD, NEWTON MA 02461 |
| Nicole Vitullo |
director, 10 percent owner |
3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121 |
| Edward F Smith |
officer: Chief Financial Officer |
C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104 |
Marinus Pharmaceuticals (Marinus Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRNS has been successfully added to your